Patents Examined by Gian P. Wang
-
Patent number: 5462862Abstract: Clustered antibiotic biosynthetic genes are employed for improvement of production of the antibiotic in microorganisms and for the isolation of other genes involved in the biosynthesis of the antibiotic. The invention is exemplified with improved production of penicillin in Penicillium chrysogenum, with the isolation of another clustered biosynthetic gene(s) and with the expression of penicillin biosynthetic genes in Acremonium chrysogenum.Type: GrantFiled: January 25, 1993Date of Patent: October 31, 1995Assignee: Gist-brocades N.V.Inventors: Martinus A. M. Groenen, Annemarie E. Veenstra, Pieter Van Solingen, Bertus P. Koekman, Lucia H. M. Van Der Voort, Juan F. Martin, Santiago Gutierrez, Bruno Diez, Emilio Alvarez, Jose L. Barredo, Christina Esmahan
-
Patent number: 5459056Abstract: A human T cell clone containing an integrated copy of HIV in a latent state, but inducible to productive replication by an activating agent is provided. The clone of the present invention allows in vitro screening of anti-HIV drugs.Type: GrantFiled: July 29, 1992Date of Patent: October 17, 1995Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Douglas M. Powell, Kathleen A. Clouse, Thomas M. Folks
-
Patent number: 5453361Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying and isolating additional members of this gene family.Type: GrantFiled: January 21, 1992Date of Patent: September 26, 1995Assignees: Regeneron Pharmaceuticals, Inc., Max Plank Gesselschaft zur Forderung der WissenschaftenInventors: George Yancopoulos, Yves-Alain Barde, Hans Thoenen, Friedrich Lottspeich, Joachim Leibrock
-
Patent number: 5444155Abstract: Monoclonal antibodies or paratope-containing portions thereof are disclosed that immunoreact with a meso diester substrate ligand and catalytically hydrolyze a single predetermined ester bond to form one of a pair of enantiomers. Methods of making and using the same are also disclosed.Type: GrantFiled: September 10, 1991Date of Patent: August 22, 1995Assignee: The Scripps Research InstituteInventors: Kim Janda, Richard A. Lerner, Samuel J. Danishefsky
-
Patent number: 5438121Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the means to generate sufficient quantities of substantially pure BDNF for clinical use. In a specific embodiment, BDNF may be used to promote the survival of substantia nigra dopaminergic neurons and basal forebrain cholinergic neurons, thereby providing a method for treating, respectively, Parkinson's disease and Alzheimer's disease. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen.Type: GrantFiled: April 25, 1991Date of Patent: August 1, 1995Assignees: Max-Planck-Gesellschaft zur Foderund der Wissenschaften e.V., Regeneron Pharmaceuticals, Inc.Inventors: Yves-Alain Barde, Joachim Leibrock, Friedrich Lottspeich, David Edgar, George Yancopoulos, Hans Thoenen
-
Patent number: 5433945Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 20, 1992Date of Patent: July 18, 1995Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5432272Abstract: The disclosure describes a method for incorporating into double stranded DNA and RNA base pairs composed of pairing units that fit the Watson-Crick geometry in that they involve a monocyclic six membered ring pairing with a fused bicyclic heterocyclic ring system composed of a five member ring fused with a six membered ring, with the orientation of the heterocycles with respect to each other and with respect to the backbone chain analogous to that found in DNA and RNA, but with a pattern of hydrogen bonds holding the base pair together different from that found in the AT and GC base pairs (a "non-standard base pair").Type: GrantFiled: October 9, 1990Date of Patent: July 11, 1995Inventor: Steven A. Benner
-
Patent number: 5427940Abstract: The present disclosure relates to the application of genetic engineering to provide artificial .beta. cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial .beta. cells, grown in liquid culture, with glucose-containing buffers.Type: GrantFiled: January 13, 1992Date of Patent: June 27, 1995Assignee: Board of Regents, The University of Texas SystemInventor: Christopher B. Newgard
-
Patent number: 5424400Abstract: An expression vector cDNA library derived from senescent cells has been used to isolate cDNA clones that encode inhibitors of DNA synthesis. Such inhibitors play a role in cellular senescence and aging. Antisense nucleic acids reduce the inhibition of DNA synthesis.Type: GrantFiled: January 3, 1994Date of Patent: June 13, 1995Assignee: Baylor College of MedicineInventor: James R. Smith
-
Patent number: 5418135Abstract: Disclosed are polypeptides which antagonize the activity of platelet-derived growth factor (PDGF). These polypeptides include an amino acid sequence sufficiently duplicative of at least a portion of the amino acid sequence of an A chain of PDGF such that the polypeptides bind a cell membrane-bound receptor for native PDGF on a cell that responds biologically to the binding of PDGF. The binding of the antagonist to the receptor is effective to inhibit PDGF binding and activity. Also disclosed are methods of preparing and using these antagonists.Type: GrantFiled: July 21, 1993Date of Patent: May 23, 1995Assignee: Creative BioMolecules, Inc.Inventor: Roy H. L. Pang
-
Patent number: 5415874Abstract: Lymphocytes of NK phenotype were cultured with stimulator cell lines in the presence of growth factor containing medium. The resulting lines and clones derived from these lines expressed CD16 and/or Leu 19, but lacked detectable CD3 or T cell receptor .gamma./.delta. complexes on the cell surface. In addition to displaying potent cytolytic activity against K562 erythroleukemia cells (a classical NK target), the vast majority of these lines and clones lysed their specific stimulator cell lines to a significantly greater extent than irrelevant cell lines. These results indicate that some CD3- lymphocytes, phenotypically indistinguishable from NK cells, can recognize and lyse allogeneic targets in a specific manner.Type: GrantFiled: October 31, 1989Date of Patent: May 16, 1995Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jeffrey R. Bender, Ruggero Pardi, Edgar G. Engleman
-
Patent number: 5413918Abstract: The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.Type: GrantFiled: August 18, 1993Date of Patent: May 9, 1995Assignee: Medical College of OhioInventor: Ervin Faulmann
-
Patent number: 5385831Abstract: Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.Type: GrantFiled: April 1, 1993Date of Patent: January 31, 1995Assignees: Zymogenetics, Inc., The Board of Regents of the University of WashingtonInventors: Eileen R. Mulvihill, Frederick S. Hagen, Khaled M. Houamed, Wolfhard Almers
-
Patent number: 5384243Abstract: The present invention relates, in general, to a method of screening agents. In particular, the present invention relates to a method of testing the cancer preventing activity of a drug and of testing an agent for its ability to prevent cell transformation.Type: GrantFiled: December 11, 1992Date of Patent: January 24, 1995Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: J. Silvio Gutkind, Keith C. Robbins
-
Patent number: 5382658Abstract: Herein described are variants of parathyroid hormone that retain significant PTH activity and are substantially resistant to trypsin and trypsin-like enzymes. The variants are useful pharmaceutically, to treat bone disorders such as osteoporosis and in other therapeutic applications. Specific embodiments of the invention include [His.sup.25 ]PTH and [His.sup.25 His.sup.26 Leu.sup.27 ]PTH.Type: GrantFiled: April 3, 1992Date of Patent: January 17, 1995Assignees: Allelix Biopharmaceuticals Inc., Glaxo Canada Inc.Inventors: K. Anne Kronis, Richard P. Bozzato
-
Patent number: 5378819Abstract: Systemin is an 18 amino acid peptide hormone that induces expression of defense genes in plants wounded mechanically or by predators including herbivores, insects, bacteria and viruses. The precursor for systemin is encoded as a 200 amino acid prosystemin molecule that has the systemin peptide sequence located near the carboxy-terminus. Both a 951 bp cDNA for prosystemin and 4526 bp genomic DNA were cloned and the organization of the gene was determined. Transgenic plants constructed with antisense prosystemin DNA fail to mount a defensive response to wounding. Transgenic plants constructed with increased copy number of prosystemin genes exhibit increase resistance to wounding. A tomato systemin polypeptide has an amino acid sequence NH.sub.3 --AVQSKPPSKRDPPKMQTD--COO--.Type: GrantFiled: March 19, 1992Date of Patent: January 3, 1995Assignee: Washington State University Research FoundationInventors: Clarence A. Ryan, Gregory L. Pearce, Barry F. McGurl
-
Patent number: 5364785Abstract: A novel bronchial or bronchiolar epithelial cell from normal neonatal rat lung has been isolated, established and maintained for multiple passages in the absence of serum, without undergoing crisis or senescence. By careful manipulation of the nutritional/hormonal microenvironment we have been able to select, from a heterogeneous population, a single epithelial cell type which can maintain highly differentiated features in vitro. This cell type has characteristics of bronchiolar epithelial cells. A clonal line, RL-65, has been selected and observed for more than 2 years in continuous culture. It has been characterized by ultrastructural, morphological and biochemical criteria.Type: GrantFiled: May 11, 1993Date of Patent: November 15, 1994Assignee: Genentech, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts
-
Patent number: 5359036Abstract: Disclosed herein are methods and means of producing novel growth hormone-like proteins derived from the pituitary gland of fishes belonging to the order Pleuronectina, the family Paralichthydae, which are useful in the growth promotion for fishes, by genetic engineering using cloned genes.Type: GrantFiled: February 15, 1991Date of Patent: October 25, 1994Assignee: Nippon Oil Company, LimitedInventors: Shusaku Sakata, Hiroshi Kawauchi, Masao Ono
-
Patent number: 5359046Abstract: Chimeric proteins and DNA sequence encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA sequences may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types.Type: GrantFiled: December 9, 1992Date of Patent: October 25, 1994Assignees: Cell Genesys, Inc., The Regents of the University of CaliforniaInventors: Daniel J. Capon, Arthur Weiss, Brian A. Irving, Margo R. Roberts, Krisztina Zsebo
-
Patent number: 5358868Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 5, 1991Date of Patent: October 25, 1994Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey